|drug1662||Inhaled nitric oxide (iNO) Wiki||1.00|
|drug2206||Nitrogen gas Wiki||0.71|
There is one clinical trial.
This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.
Description: As assessed per treating physician's discretion.Measure: Incidence of treatment emergent adverse events Time: Up to 14 days
Description: Incidence of hypoxemia and hypotension as assessed per treating physician's discretion.Measure: Incidence of adverse events Time: Up to 6 hours
Description: Incidence of increase to > 5% total methemoglobin as assessed by pulse oximetry.Measure: Incidence of methemoglobinemia Time: Up to 14 days
Description: Worsening respiratory status as defined by any one of the following: Implementation of High Flow Nasal Cannula (HFNC), non-rebreather mask, non-invasive ventilation, intubation and mechanical ventilation or need for intubation (in the event the patient is not intubated due to do not intubate (DNI) or do not resuscitate (DNR) status).Measure: Number of participants with progression of respiratory failure Time: Up to 14 days
Description: The number of days until hypoxemia is resolved as per treating physician assessmentMeasure: Time until resolution of hypoxemia Time: Up to 14 days
Description: Incidence of death during hospitalization and after discharge up to 28 daysMeasure: Incidence of mortality Time: Up to 28 days
Description: Number of days of hospitalizationMeasure: Duration of hospitalization Time: Up to 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports